BrioHealth Solutions, which develops implantable medical devices to address advanced heart failure, has secured $100 million in a strategic funding round, roping in several blue-chip investors, including HongShan and Gaorong Ventures.
Neovision Capital, which counts Shanghai-listed Nanjing Gaoke as one of its limited partners (LPs); and China-focused seed- and early-stage venture investor China Growth Capital, were among the other participating investors, according to a release on Monday.
The proceeds will be used for international expansion, product innovation, and pipeline R&D, per the release.
Founded in 2008, Suzhou-based BrioHealth aims to improve survival and quality of life for end-stage heart failure patients.
The firm, which has a wholly-owned subsidiary located in Los Angeles, focuses on the R&D of ventricular assist devices (VAD), a device designed to support the heart’s function in patients awaiting transplant.
The implantable CH-VAD left ventricular assist system (LVAS) is a new-generation fully magnetically levitated ventricular assist device (LVAD) under the product portfolio of BrioHealth. Most recently, the firm began the trial study of its BrioVAD System in the US in November 2024.
The BrioVAD System features a fully magnetically suspended blood pump, paired with uniquely engineered external components aimed at reducing adverse events and enhancing patients’ quality of life, according to the company website. Over 350 patients outside the US have been treated with a ventricular assist system that incorporates the BrioVAD Pump, the firm said.
Medical device companies in China raised a total of $505.2 million through the completion of 49 deals in Q2 this year, according to DealStreetAsia’s proprietary data. The deal value was 40.2% less than Q1’s $845.2 million, and the deal count was down by 15.5% quarter-over-quarter (QoQ).
